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Abstract
Cancer immunoprevention is based on the fact that a functioning immune system controls tumor onset and
development in humans and animals, thus leading to the idea that the enhancement of immune responses in
healthy individuals could effectively reduce cancer risk later in life. Successful primary immunoprevention of tumors
caused by hepatitis B and papilloma viruses is already implemented at the population level with specific vaccines.
The immunoprevention of human tumors unrelated to infectious agents is an outstanding challenge. Proof-of-
principle preclinical studies in genetically-modified or in carcinogen-exposed mice clearly demonstrated that
vaccines and other immunological treatments induce host immune responses that effectively control tumor onset
and progression, eventually resulting in cancer prevention. While a straightforward translation to healthy humans is
currently unfeasible, a number of pioneering clinical trials showed that cancer immunoprevention can be effectively
implemented in human cohorts affected by specific cancer risks, such as preneoplastic/early neoplastic lesions.
Future developments will see the implementation of cancer immunoprevention in a wider range of conditions at
risk of tumor development, such as the exposure to known carcinogens and genetic predispositions.
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Background
The immune system is a major player in the prevention of
diseases. Immunity is best known for the prevention of
infectious diseases, however it plays an equally important
role in the prevention of tumors. Such a role was first hy-
pothesized half a century ago, but a definitive demonstra-
tion came only at the beginning of this century, when it
was shown that severely immunodeficient mice invariably
develop tumors over time, whereas immunocompetent
mice of the same age are tumor-free [1, 2].
While mouse immunologists were struggling to devise
appropriate genetically-modified immunodeficient
mouse models, human immunologists accumulated
evidence on transplant recipients and AIDS patients,
showing that, in both cases, human immunodeficiency
brought about a strong increase in the risk of
virus-related tumors, such as Kaposi sarcoma, caused by
human herpesvirus 8, or carcinomas caused by human
papilloma viruses [3].
After 50 years of intense research, we have reached
general conclusions that apply to humans and mice: any
severe, congenital immune deficiency exposes the adult
host to a high risk of tumor onset involving all tumor
types. Partial or transient immune deficiencies entail a
correspondingly reduced tumor risk, possibly limited to
specific tumor types, such as highly immunogenic viral
tumors [4]. Under non-sterile conditions, severe primary
immune deficiencies expose the host to an early septic
death, well before the age when the tumor risk would
become manifest, hence human cancer risk related to
immune deficiency is mostly confined to secondary im-
mune deficiencies and viral tumors [5].
Just as it happens with infectious diseases, the tumor
preventive efficacy of the immune system is far from
complete and declines with age, thus contributing to the
age-related risk of cancer [6]. From a preventive point of
view, this leads to the concept of cancer immunopreven-
tion, i.e. the opportunity to further decrease tumor risk
through the stimulation of immune defenses [7, 8].
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Immunoprevention of viral and non-viral tumors
Human cancer immunoprevention is clearly divided in
two: on the one hand are tumors related to infectious
agents, for which some effective vaccines are already im-
plemented at the population level, even though some
difficulties remain, as we shall see. On the other hand
are all tumors unrelated to infectious agents (here re-
ferred to as noninfectious tumors), which represent the
bulk of human tumor burden [9], for which we are
beginning to see some early clinical application, after
two decades of tantalizing preclinical results in mouse
models [10, 11].
One issue that must be clarified in advance is that the
notion of cancer prevention, and by extension of cancer
immunoprevention, encompasses conceptually different
approaches (see [12] for a more formal definition of the
various types of prevention). Primary prevention aims at
removing cancer risk factors to reduce tumor incidence.
A classic example in the field of chemical carcinogenesis
is the avoidance of cigarette smoke, to prevent the onset
of lung cancer and many other tobacco-related tumors.
Vaccines against oncogenic viruses are a typical example
of primary cancer immunoprevention. In the field of pri-
mary cancer prevention, the use of drugs that reduce the
risk of cancer, for example by preventing exposure to
carcinogenic agents, is labeled as chemoprevention.
Given that vaccines are drugs, immunoprevention can
be also defined as a type of chemoprevention that acts
through the immune system [13]. Secondary prevention
aims at limiting cancer progression toward malignancy,
through interventions targeted at early stages of tumor
onset. Early diagnosis is the classic human application
labeled as secondary prevention, implemented through
mass screenings, for example using mammography.
However, it must be considered that early diagnosis is
only the beginning of secondary prevention, and an early
therapeutic intervention is needed to actually avoid pro-
gression to malignancy. Thus, immunological treatments
applied after an early diagnosis, to prevent tumor pro-
gression, are instances of secondary cancer immunopre-
vention [12].
When one considers that the carcinogenic process is a
continuum that goes from a normal tissue to a highly
malignant tumor, in some instances it is a matter of
definition whether a given intervention should be labeled
as primary or secondary prevention. From a practical
perspective this can result either in the reduction of
incident tumors, through the discovery of lesions labeled
as preneoplastic, or in the increase in the number of
early neoplastic lesions, eventually producing a higher
number of tumor diagnoses. From the point of view of
secondary prevention, tumor incidence is not an issue,
because what really counts is the decrease in cancer
mortality. In this review we will adopt a more
conceptual perspective, and we will consider as second-
ary prevention any intervention taking place after the
start of the carcinogenic process, regardless of whether
the underlying abnormal tissue is formally labeled as
preneoplastic or as early neoplastic.
Prevention of infection-related tumors
Outside of the laboratory, the first successful application
of vaccines to the prevention of cancer was in the late
1960s to Marek’s disease, an avian leucosis that affected
poultry farms, caused by the eponymous herpesvirus
MDV [14].
The first human cancer preventive vaccine was against
hepatitis B virus (HBV), which in a minority of infected
individuals could result in chronic hepatitis, hepatic
cirrhosis and eventually hepatocellular carcinoma. The
earliest confirmation of the tumor preventive activity of
anti-HBV vaccines came from a pediatric Taiwanese
cohort, which showed a 70% overall reduction of liver
cancer risk, further confirmed in a subsequent
long-term re-evaluation [15].
Worldwide implementation of HBV vaccination pro-
grams in the 1980s thus represents the first instance of
mass cancer immunoprevention. It might be objected
that prevention of acute HBV infection is the raison
d’être of the HBV vaccine, and that cancer prevention is
just a nice, but secondary, side effect. The point is well
taken, but certainly it does not apply to the second wave
of cancer preventive vaccines, directed against human
papillomaviruses (HPV), which are essentially oncogenic
viruses [16], hence any HPV vaccine is by definition
aimed at cancer prevention.
Mass vaccination against HPV begun in the late 2000s,
thus long-term results for what concerns cancer preven-
tion at the population level are not yet available, but the
results of approval trials, which involved tens of thou-
sands of women worldwide, showed near 100% preven-
tion of neoplastic lesions caused by the viral genotypes
included in each vaccine [17]. Furthermore, early ana-
lyses of national vaccination programs confirm sizeable
reductions in HPV prevalence [18], foreboding corre-
sponding reductions in cancer incidence.
In principle, cervical carcinoma could become the first
human cancer eradicated by immunoprevention, much
as it happened with smallpox in the late 1970s. However,
major obstacles must be overcome before this happens.
The major one is that in most countries the proportion
of subjects vaccinated each year is low, even down to
less than 50% in some US states [19]. The reasons of this
phenomenon are beyond the scope of this review, but it
is clear that, unless the worldwide level of population
compliance rises significantly, the hope to eradicate cer-
vical carcinoma through immunoprevention will remain
in the realm of dreams.
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We still don’t have vaccines approved for two major
cancer-related infectious agents, hepatitis C virus (HCV)
and Helicobacter pylori, however there are highly effica-
cious drugs that can eradicate both, effectively prevent-
ing HCV-related hepatocellular carcinoma and gastric
cancer (the efficacy of such drugs also hampers the de-
velopment of vaccines, but again this is a subject beyond
the scope of this review). Altogether, we have in our
hands the potential to prevent the vast majority of
infection-related cancers, which represent about one
sixth of the total human cancer burden [9].
Prevention of non-infectious tumors
Conversely, about 85% of all human tumors are unre-
lated to infectious agents [9]. What are the perspectives
of immunoprevention in such cases?
If one looks at animal models of cancer, the problem
is already solved: many researchers, including ourselves,
have demonstrated time and again that a variety of im-
munological treatments, administered to healthy,
cancer-prone mice, effectively prevent the onset of tu-
mors later in life [13, 20]. So, what are the obstacles to
an immediate translation to humans of the results ob-
tained in mice?
The dirty little trick in all animal studies of cancer
immunoprevention is that the researchers know in ad-
vance which type of tumor will arise in their mice, and
when it will appear, whereas humans are exposed to the
risk of many different tumor types over several decades
of their life. Basically, this means that in the near future
we are not going to have a generic “vaccine against can-
cer” to be administered to all children to reduce their
lifetime risk of cancer. However, there are several human
cohorts subject to a predictable and measurable risk of a
known tumor, who could greatly benefit from the imple-
mentation of specific vaccination programs.
In the following sections we will first summarize the
results of preclinical studies, then we will examine some
examples of the earliest clinical trials of cancer
immunoprevention.
Cancer immunoprevention in mice
The two major types of mouse models used to investigate
cancer immunoprevention are conventional mice treated
with carcinogens and cancer-prone genetically-modified
mice [13, 20]. Most studies in the past 20 years used
genetically-modified mice, mirroring the generalized
success of these model systems in all fields of biomedical
research [21]. The standard experiment sees young,
tumor-free mice undergoing immunological maneuvers
that delay tumor onset later in life, or result in a lower in-
cidence of tumors.
Positive results were obtained against a myriad of cancer
types, using either passive approaches, e.g. administration
of monoclonal antibodies, or active stimuli, which in turn
included antigen-specific vaccines, or non-antigen-specific
treatments, such as cytokines or other immunostimulants
[2, 13, 20, 22]. It could be concluded that, in mice prone
to cancer, immunoprevention is generally doable and is
not dependent on model-specific or treatment-specific ex-
perimental conditions [13, 20, 23].
The analysis of protective immunological responses re-
vealed some differences with those elicited by vaccines
used in cancer immunotherapy, which are mainly fo-
cused on cytotoxic T lymphocytes (CTL). Many studies
showed a relevant role for helper T cells, B cells and
their products, i.e. cytokines and antibodies [24]. A
major determinant could be the different time frame of
immunoprevention in comparison to immunotherapy. In
fact, immunoprevention entails immune responses that
must be ideally active during the entire life of the host,
and mouse experiments typically last from several
months to more than one year. Under these conditions a
prolonged CTL response would probably produce rele-
vant toxic side effects, whereas the humoral response
can persist indefinitely at protective levels without harm
for the host. A similar dichotomy is encountered in viral
immunity: in most instances the cure of acute infection
requires the CTL response, whereas natural prevention
of reinfection and vaccine efficacy are mainly dependent
on antibodies [25].
Target antigens
A specific aspect of cancer immunoprevention in rela-
tion to cancer immunotherapy is the choice of target an-
tigens [26]. In the field of cancer immunotherapy there
is currently much interest for neoantigens, i.e. random
alterations of normal molecules resulting from the car-
cinogenic processes [27]. However the intrinsically un-
predictable nature of neoantigens makes them
unsuitable as targets in cancer immunoprevention. It
has been argued that the best targets for cancer immu-
noprevention are oncoantigens, i.e. those molecules that
are causally involved in the carcinogenic process, be-
cause their inhibition in preneoplastic lesions or in early
tumors offers the opportunity to block tumor progres-
sion and minimizes the emergence of antigen-loss vari-
ants [2, 28–30].
The ideal target antigen for cancer immunoprevention
would be a molecule expressed only by neoplastic or
preneoplastic cells, however only a few molecules fulfill
this requirement, such as MUC1, which is differentially
glycosylated in normal and neoplastic cells [31, 32], or
HPV-encoded molecules in HPV-infected people. In
most instances the target antigen would be expressed
also by some normal cells. In this case an important
issue is the physiological role of the target antigen, be-
cause (auto)immune responses directed against targets
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that play a relevant role in the biology of the healthy
adult host are bound to provoke intolerable toxicities.
Under this respect, the HER-2 oncogene, which was ex-
tensively studied both in mice and in humans, is a good
choice, because its most important physiological role ap-
pears to be during heart embryogenesis [33], whereas
long-term inhibition in adults, as it happens during
monoclonal antibody therapy of breast cancer, is well
tolerated in the vast majority of patients [34]. Such anti-
gens would traditionally be labeled as oncofetal antigens,
but more recently the term “retired antigens” has been
proposed in relation to cancer immunoprevention [35].
Early clinical trials
We will examine here some early clinical trials demon-
strating that cancer immunoprevention is indeed trans-
latable to appropriate human contexts. A detailed
discussion of the countless clinical trials in which vac-
cines were tested as therapeutic agents against estab-
lished human tumors goes beyond the scope of this
review, in particular because most therapeutic cancer
vaccines of the past had limited efficacy against existing
human tumors [20, 36]. A renaissance of therapeutic
cancer vaccines is currently being fostered by the mo-
lecular definition of novel antigens (neoantigens) appear-
ing in individual tumors as a consequence of extensive
mutational events in the genome (“mutanome”) [37].
New therapeutic vaccines are also being combined with
immunomodulatory monoclonal antibodies [37], such as
those against CTLA-4, PD-1 and PD-L1 already in clinical
use, to remove immunosuppressive mechanisms (“im-
mune checkpoints”) that hamper the induction of effective
anti-tumor immune responses [38]. We expect that the
analysis of current and forthcoming therapeutic trials will
reveal which advances in the field of therapeutic vaccines
will be applicable to prophylactic vaccines.
Successful proof-of-principle preclinical studies out-
lined in the previous sections have opened the way to a
few pioneering clinical trials which demonstrate that
immunoprevention is indeed feasible in a variety of hu-
man conditions at risk of cancer development [30, 39]. It
must be kept in mind that cancer prevention trials entail
specific hurdles in comparison with therapeutic trials:
even in populations at risk, tumor onset is relatively rare,
hence large number of volunteers need to be recruited,
furthermore, when the subjects harbor preneoplastic or
early neoplastic lesions, spontaneous regression is com-
mon, even in the absence of any treatment, mandating
the need for controlled trials.
Dr. Olivera J. Finn and Robert E. Schoen in Pittsburgh
are investigating anti-MUC1 vaccines for the prevention
of colorectal carcinogenesis. A pilot clinical trial assessed
vaccine immunogenicity in patients with intestinal
polyps [40, 41], paving the way to a currently ongoing
trial (ClinicalTrials.gov identifier NCT01720836) that
aims at preventing polyp onset in tumor-free individuals
who previously had a polyp removed. Immunological
studies of patients enrolled in the pilot trial revealed that
vaccination elicited tumor-specific, cytotoxic anti-MUC1
antibodies [41], thus providing a human counterpart of
the preventive mechanisms found in mouse studies of
primary immunoprevention (see above, Cancer immuno-
prevention in mice).
The introduction of prophylactic HPV vaccination of
girls should not obscure the fact that millions of adult
women worldwide harbor a chronic HPV infection that
natural immune responses were unable to eradicate, ex-
posing them to a sizeable risk of cervical carcinoma [39].
Prophylactic HPV vaccines, directed against late (L)
HPV proteins, lack therapeutic activity against chronic
HPV infections [42], thus underlining the need for
therapeutic vaccines targeting early (E) HPV proteins
[43–45]. One such vaccine, made of electroporated plas-
mids encoding HPV16/18 oncogenes E6 and E7, in-
creased the occurrence of cervical intraepithelial
neoplasia (CIN) regression and of HPV clearance in
women harboring HPV-positive CIN 2 or CIN 3 [45].
In mammary carcinogenesis the most obvious target
for cancer immunoprevention is HER-2. A neoadjuvant
clinical trial conducted in women with HER-2-positive
ductal carcinoma in situ (DCIS) undergoing resection
within 4–6 weeks showed that the administration of au-
tologous dendritic cells pulsed with HER-2 peptides in
vitro elicited anti-HER-2 immune responses in most pa-
tients. At surgery, one fourth of all patients had complete
tumor regression, the best results was in the ER-negative
group, with 38% of complete tumor regressions [46]. Other
ongoing vaccination trials are testing an immunodominant
HER-2 peptide (nelipepimut-S, also known as E75) in com-
bination with granulocyte-macrophage colony stimulating
factor either in a neoadjuvant setting against DCIS (Clini-
calTrials.gov NCT02636582) or to prevent the develop-
ment of metastases after conventional therapy in more
advanced, node-positive patients (ClinicalTrials.gov
NCT01479244).
A further area in which immunoprevention is already
being tested in the clinical arena is that of hematopoietic
diseases at risk of progression. After an early clinical trial
as single agent [47] a multiepitopic peptide vaccine is
being tested in patients with smoldering myeloma in
combination with other therapeutic agents to prevent
progression to multiple myeloma (ClinicalTrials.gov
NCT02886065).
Conclusions and perspectives
The results of countless mouse studies have demon-
strated that the risk of cancer development can be
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significantly reduced by appropriate treatments that en-
hance immune defenses.
Primary cancer immunoprevention in healthy humans
is currently restricted to tumors related to infectious
agents, such as HBV and HPV, which cause about
one-sixth of the whole tumor burden. Primary preven-
tion of tumors unrelated to infectious agents is presently
unfeasible in the general human population, mainly be-
cause it would require vaccines completely devoid of sig-
nificant toxicities that should confer long-term protection
against the risk of a wide spectrum of tumors histotypes.
Some hope in this direction comes from the possibility to
elicit immune responses against the products of some
common mutations in cancer genes, such as RAS or dom-
inant negative p53 [48, 49], but proof-of-principle results
in humans are still lacking.
A series of pioneering clinical trials have shown that
immunoprevention can be successfully applied to selected
human groups in which the risk of a specific tumor type is
much higher than in the general population.
Future developments of these concepts might lead to a
widespread implementation of cancer immunopreven-
tion, because epidemiological, molecular and genetic
studies of the past 100 years have uncovered a huge
number of human beings with specific cancer risks, in-
cluding individuals previously exposed to potent carcin-
ogens, such as asbestos workers or tobacco smokers;
patients with preneoplastic or early neoplastic conditions
at risk of progression; individuals with genetic predispo-
sitions, like microsatellite instability or BRCA mutations.
Finally, most lifestyles (e.g. diet, physical activity) and
chemopreventive treatments conducive to reductions in
cancer risk also seem to have beneficial effects on the
immune system [50], leading to the prediction that com-
plex preventive regimes combining behavioral, chemo-
preventive and immunopreventive components could
have additive or synergistic effects.
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